Jones DR - Search Results

1

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.

Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, Hall SD. Gorski JC, et al. Among authors: jones dr. Clin Pharmacol Ther. 1998 Aug;64(2):133-43. doi: 10.1016/S0009-9236(98)90146-1. Clin Pharmacol Ther. 1998. PMID: 9728893

2

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.

Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. Ward BA, et al. Among authors: jones dr. J Pharmacol Exp Ther. 2003 Jul;306(1):287-300. doi: 10.1124/jpet.103.049601. Epub 2003 Apr 3. J Pharmacol Exp Ther. 2003. PMID: 12676886

3

Mechanism-based inactivation of CYP3A by HIV protease inhibitors.

Ernest CS 2nd, Hall SD, Jones DR. Ernest CS 2nd, et al. Among authors: jones dr. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91. doi: 10.1124/jpet.104.075416. Epub 2004 Nov 2. J Pharmacol Exp Ther. 2005. PMID: 15523003

4

Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite.

Zhang X, Quinney SK, Gorski JC, Jones DR, Hall SD. Zhang X, et al. Among authors: jones dr. Drug Metab Dispos. 2009 Aug;37(8):1587-97. doi: 10.1124/dmd.109.026658. Epub 2009 May 6. Drug Metab Dispos. 2009. PMID: 19420129 Clinical Trial.

5

Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily.

Gorski JC, Jones DR, Wrighton SA, Hall SD. Gorski JC, et al. Among authors: jones dr. Biochem Pharmacol. 1994 Jul 5;48(1):173-82. doi: 10.1016/0006-2952(94)90237-2. Biochem Pharmacol. 1994. PMID: 8043020

6

Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.

Jones DR, Gorski JC, Haehner BD, O'Mara EM Jr, Hall SD. Jones DR, et al. Clin Pharmacol Ther. 1996 Oct;60(4):374-84. doi: 10.1016/S0009-9236(96)90194-0. Clin Pharmacol Ther. 1996. PMID: 8873685 Clinical Trial.

7

Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone.

Gorski JC, Jones DR, Wrighton SA, Hall SD. Gorski JC, et al. Among authors: jones dr. Xenobiotica. 1997 Mar;27(3):243-56. doi: 10.1080/004982597240578. Xenobiotica. 1997. PMID: 9141232

8

The interaction of diltiazem with lovastatin and pravastatin.

Azie NE, Brater DC, Becker PA, Jones DR, Hall SD. Azie NE, et al. Among authors: jones dr. Clin Pharmacol Ther. 1998 Oct;64(4):369-77. doi: 10.1016/S0009-9236(98)90067-4. Clin Pharmacol Ther. 1998. PMID: 9797793 Clinical Trial.

9

Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.

Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, Hall SD. Jones DR, et al. J Pharmacol Exp Ther. 1999 Sep;290(3):1116-25. J Pharmacol Exp Ther. 1999. PMID: 10454485

10

Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily.

Gorski JC, Jones DR, Hamman MA, Wrighton SA, Hall SD. Gorski JC, et al. Among authors: jones dr. Xenobiotica. 1999 Sep;29(9):931-44. doi: 10.1080/004982599238173. Xenobiotica. 1999. PMID: 10548453

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,441 results

Search Page

Filters